Table 6.
Impacts of clinicopathologic parameters on RFS during maintenance therapy in 47 APL patients receiving ATRA+IDA as an induction regimen
| Clinicopathologic parameters | 3-year RFS | P-value (log-rank) |
|---|---|---|
| Sex | 0.4381 | |
| Male | 0.8337 | |
| Female | 0.9545 | |
| Age (years) | 0.7301 | |
| ≤40 | 0.8696 | |
| >40 | 0.9079 | |
| WBC count (×109/L) | 0.7274 | |
| ≤5 | 0.8904 | |
| >5 | 0.8889 | |
| Platelet count (×109/L) | 0.2928 | |
| ≤40 | 0.8436 | |
| >40 | 1.0000 | |
| Hemoglobin (g/L) | 0.1158 | |
| <100 | 0.9351 | |
| ≥100 | 0.7857 | |
| Maintenance regimens | 0.0264 | |
| ATRA+As2O3 | 1.0000 | |
| ATRA+chemotherapy | 0.7958 |
Abbreviations: APL, acute promyelocytic leukemia; As2O3, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; RFS, relapse-free survival; WBC, white blood cell.